GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (FRA:PCJ) » Definitions » Short Percentage of Float

Abeona Therapeutics (FRA:PCJ) Short Percentage of Float


View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Abeona Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Abeona Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abeona Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's Short Percentage of Float falls into.


Abeona Therapeutics (FRA:PCJ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (FRA:PCJ) » Definitions » Short Percentage of Float
Comparable Companies
VANI HOOK PMVP ALLK GNLX ALVR GRTS ELTX CRIS ALRN OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
ABEO:USA
Address
1330 Avenue of the Americas, 33rd Floor, New York, NY, USA, 10019
Website
https://www.abeonatherapeutics.com
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its lead clinical programs consist of EB-101, autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, adeno-associated virus-based gene therapy for Sanfilippo syndrome type A, and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B.

Abeona Therapeutics (FRA:PCJ) Headlines

No Headlines